Product-specific advice (Benserazide+levo­dopa) [Design Issues]

posted by Mauricio Sampaio  – Brazil, 2018-01-10 17:22 (2349 d 12:45 ago) – Posting: # 18162
Views: 2,947

Dear Mikalai,

First of all we need remember what is the Benserazide and its function in this fixed combination.

Benserazide is a DOPA decarboxylase inhibitor, which is unable to cross the blood–brain barrier. It is a peripherally-acting aromatic L-amino acid decarboxylase. So, Benserazide is a lyase enzyme and catalyzes several different decarboxylation reactions.

Benserazide inhibits the peripheral conversion of l-dopa into dopamine. This allows dopamine to build up solely in the brain and the adverse effects caused by peripheral dopamine, such as vasoconstriction, nausea, and arrhythmia, are minimized.

❝ We approached several experts to write a protocol of the study. However, they informed us that there is a substantial lack of information on the pharmacokinetics of benserazide to finalize the protocol.


I disagree!!! :no:

Benserazide show a rapid increase and rapid decrease in its plasma concentration and the pharmacokinetics of systemic benserazide does not seem to contribute to the elimination of levodopa. (look the references below)

Therefore, Benserazide has non significant therapeutic effect on its own, and its effect occurs synergically in combination with levodopa (used in the management of Parkinson's disease). If Benserazide (isolated/alone) has not therapeutic effect, why I need to quantify in bioequivalence study? Forget quantification of Benzeraside! :vomit:

In conclusion, your plan (the best design) to conduct the bioequivalence study of levodopa and benserazide must quantify only levodopa and its metabolite 3-O-methyldopa. Why ? :confused: Because, 3-O-methyldopa is one of the most important active metabolites of L-DOPA and its half-life (15 hours approximately) is longer than L-DOPA's half-life, which is about one hour. This means that the accumulate of 3-O-methyldopa in plasma and in the brain help chronic patients suffering from Parkinson's disease. :cool:

Pay attention :waving:: Both components (levodopa and its metabolite 3-O-methyldopa) need reach the target of bioequivalence acceptance criteria.

Refereces:

1) http://onlinelibrary.wiley.com/doi/10.1111/ncn3.152/pdf
2) http://portal.anvisa.gov.br/documents/33836/2819922/Lista+2+03.06.2016.pdf/5ced804f-eb03-4d18-86a4-9ec60eb35f90?version=1.0

:ok:

Complete thread:

UA Flag
Activity
 Admin contact
23,057 posts in 4,840 threads, 1,641 registered users;
138 visitors (0 registered, 138 guests [including 65 identified bots]).
Forum time: 07:08 CEST (Europe/Vienna)

If you tell the truth you don’t have to remember anything.    Mark Twain

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5